The advantages of frontotemporal degeneration drug development (part 2 of frontotemporal degeneration: The next therapeutic frontier)

✍ Scribed by Boxer, Adam L.; Gold, Michael; Huey, Edward; Hu, William T.; Rosen, Howard; Kramer, Joel; Gao, Fen-Biao; Burton, Edward A.; Chow, Tiffany; Kao, Aimee; Leavitt, Blair R.; Lamb, Bruce; Grether, Megan; Knopman, David; Cairns, Nigel J.; Mackenzie, Ian R.; Mitic, Laura; Roberson, Erik D.; Van Kammen, Daniel; Cantillon, Marc; Zahs, Kathleen; Jackson, George; Salloway, Stephen; Morris, John; Tong, Gary; Feldman, Howard; Fillit, Howard; Dickinson, Susan; Khachaturian, Zaven S.; Sutherland, Margaret; Abushakra, Susan; Lewcock, Joseph; Farese, Robert; Kenet, Robert O.; LaFerla, Frank; Perrin, Steve; Whitaker, Steve; Honig, Lawrence; Mesulam, Marsel M.; Boeve, Brad; Grossman, Murray; Miller, Bruce L.; Cummings, Jeffrey L.

• Book ID: 122626920
• Publisher: Elsevier Science
• Year: 2012
• Tongue: English
• Weight: 399 KB
• Volume: 9
• Category: Article
• ISSN: 1552-5260
• DOI: 10.1016/j.jalz.2012.03.003